Yuki Takamatsu

Yuki Takamatsu

Auto-generated profile, based on publicly available information

Yuki Takamatsu

Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SHShin-ichiro Hattori
Shin-ichiro Hattori
NHNobuyo Higashi-Kuwata
Nobuyo Higashi-Kuwata
HHHironori Hayashi
Hironori Hayashi
SASrinivasa Rao Allu
Srinivasa Rao Allu
JRJakka Raghavaiah
Jakka Raghavaiah
HMHiroaki Mitsuya
Hiroaki Mitsuya
Except remdesivir, no specific antivirals for SARS-CoV-2 infection are currently available. Here, we characterize two small-molecule-compounds, named GRL-1720 and 5h, containing an indoline and indole moiety, respectively, which target the SARS-CoV-2 main protease (Mpro). We use VeroE6 cell-based assays with RNA-qPCR, cytopathic assays, and immunocytochemistry and show both compounds to block the infectivity of SARS-CoV-2 with EC50 values of 15 ± 4 and 4.2 ± 0.7 μM for GRL-1720 and 5h, respectively. Remdesivir permitted viral breakthrough at high concentrations; however, compound 5h completely blocks SARS-CoV-2 infection in vitro without viral breakthrough or detectable cytotoxicity. Combination of 5h and remdesivir exhibits synergism against SARS-CoV-2. Additional X-ray structural analysis show that 5h forms a covalent bond with Mpro and makes polar interactions with multiple active site amino acid residues. The present data suggest that 5h might serve as a lead Mpro inhibitor for the development of therapeutics for SARS-CoV-2 infection.

25 August 2020 in mBio
Verified
Journal Article
Open access
PDF file
SHShin-Ichiro Hattori
Shin-Ichiro Hattori
NHNobuyo Higshi-Kuwata
Nobuyo Higshi-Kuwata
JRJakka Raghavaiah
Jakka Raghavaiah
DDDebananda Das
Debananda Das
HBHaydar Bulut
Haydar Bulut
HMHiroaki Mitsuya
Hiroaki Mitsuya
Targeting the main protease (M pro ) of SARS-CoV-2, we identified two indole-chloropyridinyl-ester derivatives, GRL-0820 and GRL-0920, active against SARS-CoV-2, employing RNA-qPCR and immunocytochemistry and show that the two compounds exerted potent activity against SARS-CoV-2. While GRL-0820 and remdesivir blocked SARS-CoV-2 infection, viral breakthrough occurred as examined with immunocytochemistry. In contrast, GRL-0920 completely blocked the infectivity and cytopathic effect of SARS-CoV-2 without significant toxicity. Structural modeling showed that indole and chloropyridinyl of the derivatives interacted with two catalytic dyad residues of M pro , Cys145 and His41, resulting in covalent bonding, which was verified using HPLC/MS. The present data should shed light on the development of therapeutics for COVID-19, and optimization of GRL-0920 based on the present data is essential to develop more-potent anti-SARS-CoV-2 compounds for treating COVID-19.

25 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
NHNobuyo Higashi-Kuwata
Nobuyo Higashi-Kuwata
KTKohei Tsuji
Kohei Tsuji
HHHironori Hayashi
Hironori Hayashi
HBHaydar Bulut
Haydar Bulut
MKMaki Kiso
Maki Kiso
HMHiroaki Mitsuya
Hiroaki Mitsuya
: COVID-19 caused by SARS-CoV-2 has continually been serious threat to public health worldwide. While a few anti-SARS-CoV-2 therapeutics are currently available, their antiviral potency is not sufficient. Here, we identify two orally available 4-fluoro-benzothiazole-containing small molecules, TKB245 and TKB248, which specifically inhibit the enzymatic activity of main protease (Mpro) of SARS-CoV-2 and significantly more potently block the infectivity and replication of various SARS-CoV-2 strains than nirmatrelvir, molnupiravir, and ensitrelvir in cell-based assays employing various target cells. Both compounds also block the replication of Delta and Omicron variants in human-ACE2-knocked-in mice. Native mass spectrometric analysis reveals that both compounds bind to dimer Mpro, apparently promoting Mpro dimerization. X-ray crystallographic analysis shows that both compounds bind to Mpro’s active-site cavity, forming a covalent bond with the catalytic amino acid Cys-145 with the 4-fluorine of the benzothiazole moiety pointed to solvent. The data suggest that TKB245 and TKB248 might serve as potential therapeutics for COVID-19 and shed light upon further optimization to develop more potent and safer anti-SARS-CoV-2 therapeutics.

17 October 2017 in eLife
Verified
Journal Article
Open access
MAManabu Aoki
Manabu Aoki
HHHironori Hayashi
Hironori Hayashi
KRKalapala Venkateswara Rao
Kalapala Venkateswara Rao
DDDebananda Das
Debananda Das
NHNobuyo Higashi-Kuwata
Nobuyo Higashi-Kuwata
HMHiroaki Mitsuya
Hiroaki Mitsuya
Antiretroviral therapy for HIV-1 infection/AIDS has significantly extended the life expectancy of HIV-1-infected individuals and reduced HIV-1 transmission at very high rates. However, certain individuals who initially achieve viral suppression to undetectable levels may eventually suffer treatment failure mainly due to adverse effects and the emergence of drug-resistant HIV-1 variants. Here, we report GRL-142, a novel HIV-1 protease inhibitor containing an unprecedented 6-5-5-ring-fused crown-like tetrahydropyranofuran, which has extremely potent activity against all HIV-1 strains examined with IC50 values of attomolar-to-picomolar concentrations, virtually no effects on cellular growth, extremely high genetic barrier against the emergence of drug-resistant variants, and favorable intracellular and central nervous system penetration. GRL-142 forms optimum polar, van der Waals, and halogen bond interactions with HIV-1 protease and strongly blocks protease dimerization, demonstrating that combined multiple optimizing elements significantly enhance molecular and atomic interactions with a target protein and generate unprecedentedly potent and practically favorable agents.

29 June 2015 in Hepatology
Verified
Journal Article
Open access
PDF file
YTYuki Takamatsu
Yuki Takamatsu
YTYasuhito Tanaka
Yasuhito Tanaka
SKSatoru Kohgo
Satoru Kohgo
SMShuko Murakami
Shuko Murakami
KSKamalendra Singh
Kamalendra Singh
HMHiroaki Mitsuya
Hiroaki Mitsuya
Certain nucleoside/nucleotide reverse transcriptase (RT) inhibitors (NRTIs) are effective against human immunodeficiency virus type 1 (HIV‐1) and hepatitis B virus (HBV). However, both viruses often acquire NRTI resistance, making it crucial to develop more‐potent agents that offer profound viral suppression. Here, we report that 4′‐C‐cyano‐2‐amino‐2′‐deoxyadenosine (CAdA) is a novel, highly potent inhibitor of both HBV (half maximal inhibitory concentration [IC50] = 0.4 nM) and HIV‐1 (IC50 = 0.4 nM). In contrast, the approved anti‐HBV NRTI, entecavir (ETV), potently inhibits HBV (IC50 = 0.7 nM), but is much less active against HIV‐1 (IC50 = 1,000 nM). Similarly, the highly potent HIV‐1 inhibitor, 4′‐ethynyl‐2‐fluoro‐2′‐deoxyadenosine (EFdA; IC50 = 0.3 nM) is less active against HBV (IC50 = 160 nM). Southern analysis using Huh‐7 cells transfected with HBV‐containing plasmids demonstrated that CAdA was potent against both wild‐type (IC50 = 7.2 nM) and ETV‐resistant HBV (IC50 = 69.6 nM for ), whereas ETV failed to reduce DNA even at 1 μM. Once‐daily peroral administration of CAdA reduced viremia (P = 0.0005) in human‐liver‐chimeric/ –infected mice, whereas ETV completely failed to reduce viremia. None of the mice had significant drug‐related body‐weight or serum human‐albumin concentration changes. Molecular modeling suggests that a shallower HBV‐RT hydrophobic pocket at the polymerase active site can better accommodate the slightly shorter 4′‐cyano of CAdA‐triphosphate (TP), but not the longer 4′‐ethynyl of EFdA‐TP. In contrast, the deeper HIV‐1‐RT pocket can efficiently accommodate the 4′‐substitutions of both NRTIs. The ETV‐TP's cyclopentyl ring can bind more efficiently at the shallow HBV‐RT binding pocket. Conclusion: These data provide insights on the structural and functional associations of HBV‐ and HIV‐1‐RTs and show that CAdA may offer new therapeutic options for HBV patients. (Hepatology 2015;62:1024‐1036)

2 May 2018 in mBio
Verified
Journal Article
Open access
PDF file
MAManabu Aoki
Manabu Aoki
DDDebananda Das
Debananda Das
HHHironori Hayashi
Hironori Hayashi
HAHiromi Aoki-Ogata
Hiromi Aoki-Ogata
YTYuki Takamatsu
Yuki Takamatsu
HMHiroaki Mitsuya
Hiroaki Mitsuya
Darunavir (DRV) has bimodal activity against HIV-1 protease, enzymatic inhibition and protease dimerization inhibition, and has an extremely high genetic barrier against development of drug resistance. We previously generated a highly DRV-resistant HIV-1 variant (HIV DRV R P51 ). We also reported that four amino acid substitutions (V32I, L33F, I54M, and I84V) identified in the protease of HIV DRV R P51 are largely responsible for its high-level resistance to DRV. Here, we attempted to elucidate the role of each of the four amino acid substitutions in the development of DRV resistance. We found that V32I is a key substitution, which rarely occurs, but once it occurs, it predisposes HIV-1 to develop high-level DRV resistance. When two infectious recombinant HIV-1 clones carrying I54M and I84V (rHIV I54M and rHIV I84V , respectively) were selected in the presence of DRV, V32I emerged, and the virus rapidly developed high-level DRV resistance. rHIV V32I also developed high-level DRV resistance. However, wild-type HIV NL4-3 (rHIV WT ) failed to acquire V32I and did not develop DRV resistance. Compared to rHIV WT , rHIV V32I was highly susceptible to DRV and had significantly reduced fitness, explaining why V32I did not emerge upon selection of rHIV WT with DRV. When the only substitution is at residue 32, structural analysis revealed much stronger van der Waals interactions between DRV and I-32 than between DRV and V-32. These results suggest that V32I is a critical amino acid substitution in multiple pathways toward HIV-1’s DRV resistance development and elucidate, at least in part, a mechanism of DRV’s high genetic barrier to development of drug resistance. The results also show that attention should be paid to the initiation or continuation of DRV-containing regimens in people with HIV-1 containing the V32I substitution. IMPORTANCE Darunavir (DRV) is the only protease inhibitor (PI) recommended as a first-line therapeutic and represents the most widely used PI for treating HIV-1-infected individuals. DRV possesses a high genetic barrier to development of HIV-1’s drug resistance. However, the mechanism(s) of the DRV’s high genetic barrier remains unclear. Here, we show that the preexistence of certain single amino acid substitutions such as V32I, I54M, A71V, and I84V in HIV-1 protease facilitates the development of high-level DRV resistance. Interestingly, all in vitro -selected highly DRV-resistant HIV-1 variants acquired V32I but never emerged in wild-type HIV (HIV WT ), and V32I itself rendered HIV-1 more sensitive to DRV and reduced viral fitness compared to HIV WT , strongly suggesting that the emergence of V32I plays a critical role in the development of HIV-1’s resistance to DRV. Our results would be of benefit in the treatment of HIV-1-infected patients receiving DRV-containing regimens.